Search clinical trials for: Paclitaxel (Taxol)

Total 4086 results

NovoCure Ltd.

Completed

Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)

Ovarian Cancer

United States, Israel, Belgium, Netherlands, Hungary, Germany, Poland, Canada, Austria, Czechia, Italy, Spain, Switzerland
Hamamatsu University

Completed

Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Japan
Ira Winer

Recruiting

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Malignant Ovarian Epithelial Tumor | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian... and other conditions

United States
Loyola University

Active, not recruiting

Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer

Endometrial Cancer

United States
NYU Langone Health

Terminated

Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

United States
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma
Hanmi Pharmaceutical Company Limited

Unknown

A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors

Breast Cancer | Gastric Cancer | Unspecified Adult Solid Tumor, Protocol Specific

Korea, Republic of
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Masonic Cancer Center, University of Minnesota

Terminated

Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
AstraZeneca

Withdrawn

Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

Cancer | Non Small Cell Lung Cancer | Epithelial Ovarian Cancer

Japan
AA Secord

Completed

PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
New Mexico Cancer Care Alliance

Completed

A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes

Supportive | Ill-defined Sites

United States
Haider Mahdi

Not yet recruiting

Antitumor Activity of Neoadjuvant Chemotherapy With or Without BINTRAFUSP ALFA in Patients With Metastatic Advanced Stage Ovarian Cancer

Ovarian Cancer

United States
Medstar Health Research Institute

Completed

Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung Cancer

Lung Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer (S0009)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer
University of Nebraska
National Cancer Institute (NCI)

Completed

Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer

Thyroid Gland Anaplastic Carcinoma

United States
Midwest Cardiovascular Research Foundation
Spectranetics Corporation

Unknown

Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention (PacTAP)

Peripheral Arterial Disease | Restenosis

United States
Sun Yat-sen University

Recruiting

Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006) (EC-CRT-006)

Esophagus Cancer

China
AstraZeneca

Completed

Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients

Gastric Cancer

Korea, Republic of
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma

Thymic Carcinoma | Thymoma

United States
AstraZeneca

Active, not recruiting

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Ovarian Cancer

United States, Czechia, Italy, Belgium, Canada, Germany, Peru, Spain, Japan, Netherlands, United Kingdom, Australia
University of Wisconsin, Madison

Completed

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

Breast Neoplasm Female

United States
Lahey Clinic
National Evaluation System for health Technology Coordinating Center (NESTcc) and other collaborators

Completed

Real-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Arterial Disease

Peripheral Arterial Disease

United States
Swiss Group for Clinical Cancer Research

Completed

LDE225 and Paclitaxel in Solid Tumors

Ovarian Cancer | Solid Tumor

Switzerland
M.D. Anderson Cancer Center

Completed

Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement

Advanced Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

Ovarian Cancer
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
University of Texas Southwestern Medical Center

Terminated

Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer

Breast Cancer

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Suspended

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Invasive Breast Carcinoma | HER2/Neu Negative | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIC Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States
Amgen

Completed

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States, France, Italy, Spain, United Kingdom, Belgium, Canada, Poland, Switzerland, Korea, Republic of, Russian Federation, Hong Kong, Portugal, South Africa, Israel, Romania, Bulgaria, Greece, Australia, Sweden, Japan, Latvia and more
Dana-Farber Cancer Institute
Incyte Corporation

Completed

Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca

Metastatic Breast Cancer | Recurrent Breast Cancer

United States
NewLink Genetics Corporation

Terminated

A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian Cancer

United States
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Zhongshan People's Hospital... and other collaborators

Recruiting

Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) (EC-CRT-002)

Esophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell Carcinoma

China
University of Maryland, Baltimore
Bristol-Myers Squibb

Completed

Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)

Cancer of Head and Neck

United States
Eli Lilly and Company
University of Colorado, Denver; Indiana University; Greenwich Hospital

Completed

Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
ARCAGY/ GINECO GROUP
Novartis

Completed

Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer (TAPAZ)

Ovarian Cancer

France
RenJi Hospital

Completed

Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer (SHPD001)

Inflammatory Breast Cancer | Invasive Ductal Breast Cancer | Tubular Breast Cancer | Mucinous Breast Cancer

China
Patrick Kelly

Completed

Effects of Paclitaxel on Intimal Hyperplasia (Pac1)

Peripheral Vascular Disease

United States
GlaxoSmithKline

Completed

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

Neoplasms, Breast

United States
NYU Langone Health

Completed

Phase II Study for Solid Metastatic Tumors

Breast Cancer | Solid Tumor | Metastatic Breast Cancer
National Cancer Institute (NCI)

Completed

Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Swiss Group for Clinical Cancer Research

Completed

Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Lung Cancer

Switzerland
National Cancer Institute (NCI)

Completed

17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor

Unspecified Adult Solid Tumor, Protocol Specific

United States
Chang Gung Memorial Hospital
Asian Gynecologic Oncology Group; Taiwanese Gynecologic Oncology Group

Recruiting

Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy

Cervical Cancer

Taiwan
Instituto do Cancer do Estado de São Paulo

Withdrawn

Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer

Breast Cancer | HER-2 Positive Breast Cancer

Brazil
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Recurrent Esophageal Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Esophageal Cancer AJCC v7 | Metastatic Esophageal Squamous Cell Carcinoma | Metastatic Esophageal Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Recurrent Esophageal Adenocarcinoma and other conditions

United States
Ohio State University Comprehensive Cancer Center

Completed

Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer (KETO-CARE)

Stage IV Breast Cancer AJCC v6 and v7

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Completed

Alisertib in Chemotherapy-pretreated Urothelial Cancer

Transitional Cell Carcinoma | Bladder Cancer

Italy

Search clinical trials for: Paclitaxel (Taxol)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations